At a glance
ClinicalIndex Comparison RecordN/ACompleted· 935 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Observational Study to Evaluate Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis in Routine Clinical Practice
In Brief
An observational study for Osteoporosis, Age-Related. Completed, enrolled 935 participants across 89 sites in 2 countries.
Detailed Summary
The objective of this study was to describe persistence with Prolia® 60 mg administered subcutaneously (SC) every 6 months (Q6M) at 12 and 24 months.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis, Age-Related
CountriesCanada, United States
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2011
Primary CompletionApr 2014
Study CompletionApr 2014
First PostedApr 2016
TodayJul 2026
First PostedApr 8, 2016
Enrollment StartJul 6, 2011
Primary CompletionApr 7, 2014
Study CompletionApr 14, 2014
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 10.2 years ago